Does Januvia (sitagliptin) cause weight gain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Does Januvia (Sitagliptin) Cause Weight Gain?

No, Januvia (sitagliptin) does not cause weight gain—it is weight neutral or may lead to modest weight loss. This is a key advantage when selecting diabetes medications, particularly for overweight or obese patients.

Weight Effect Profile

Sitagliptin, as a DPP-4 inhibitor, is consistently classified as weight neutral across major clinical guidelines 1, 2. The Endocrine Society explicitly states that "Dipeptidyl peptidase IV (DPP-4) inhibitors appear to be weight neutral or may lead to minimal weight change" 1.

Clinical Trial Evidence

The weight effects of sitagliptin have been well-documented in multiple studies:

  • A retrospective analysis of 5,861 sitagliptin-treated patients showed an average weight loss of 1.1 kg, compared to 3.0 kg loss with exenatide and 0.6 kg gain with insulin 1.

  • In a 52-week head-to-head comparison with glipizide, patients on sitagliptin exhibited a mean weight decrease of 1.5 kg, while those on glipizide gained 1.1 kg 3. This 2.6 kg difference was statistically significant.

  • A 2-year study confirmed sustained weight loss of 1.6 kg with sitagliptin versus weight gain of 0.7 kg with glipizide when added to metformin 4.

  • When combined with metformin versus pioglitazone alone, the sitagliptin-metformin combination resulted in weight loss of 1.4 kg, while pioglitazone monotherapy led to weight gain of 3.0 kg 1.

  • A 2021 meta-analysis of 18 randomized controlled trials (2,009 participants) demonstrated that sitagliptin administration led to significant weight reduction (mean difference -0.99 kg) and BMI reduction (mean difference -0.23 kg/m²) compared to placebo, with greater effects when treatment exceeded 6 months 5.

Comparison to Other Diabetes Medications

Understanding sitagliptin's weight profile requires context within the broader diabetes medication landscape 1:

Medications causing significant weight gain (avoid if weight is a concern):

  • Insulin: can cause up to 10 kg gain in 3-6 months 1
  • Sulfonylureas (glipizide, glyburide): 1.8-3.0 kg gain 1
  • Thiazolidinediones (pioglitazone): 3.0 kg gain 1

Weight-neutral options:

  • DPP-4 inhibitors (sitagliptin, vildagliptin): 0 to -1.1 kg 1, 6
  • Alpha-glucosidase inhibitors: minimal change 1

Medications promoting weight loss:

  • GLP-1 agonists (liraglutide, semaglutide): -2.2 to -8.5 kg 7
  • SGLT-2 inhibitors: -2.5 kg 7
  • Metformin: -2.1 kg 1, 6

Clinical Implications

When selecting glucose-lowering medications for overweight or obese patients with type 2 diabetes, the American Diabetes Association recommends considering the medication's effect on weight 2. Sitagliptin represents an excellent choice when:

  • Weight neutrality is desired but GLP-1 agonists are not tolerated or contraindicated
  • Avoiding hypoglycemia risk is important (sitagliptin has only 4.9% hypoglycemia rate versus 32% with sulfonylureas) 3
  • Oral administration is preferred over injectable options
  • Gastrointestinal side effects from metformin or GLP-1 agonists are problematic 1

Important Caveats

The weight effect can be influenced by combination therapy 3:

  • When sitagliptin is combined with pioglitazone, the weight gain from pioglitazone (1.9 kg) is only partially offset, resulting in net gain of 1.1 kg for the combination 3
  • However, when combined with metformin, the weight-neutral or weight-loss effects are preserved 1

Recent data from the GRADE trial showed that initial weight loss with sitagliptin (-1.07 kg in first year) was followed by gradual weight decrease in subsequent years, similar to other diabetes medications 8. This suggests the weight-neutral effect is durable over time.

Bottom Line

Sitagliptin should be considered a weight-favorable option in diabetes management, particularly when compared to insulin, sulfonylureas, or thiazolidinediones 1, 2. While it doesn't produce the dramatic weight loss seen with GLP-1 agonists or SGLT-2 inhibitors, its weight-neutral profile combined with low hypoglycemia risk, oral administration, and good tolerability makes it an appropriate choice for many patients with type 2 diabetes 9.

References

1
Guideline

pharmacological management of obesity: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Related Questions

What class of medication is Januvia (sitagliptin)?
Should I hold pioglitazone preoperatively?
Why is this 54‑year‑old overweight male with hypertension, atherogenic dyslipidemia, elevated random blood glucose, massive glucosuria, mild proteinuria, and normal thyroid function diagnosed with type 2 diabetes mellitus?
Does pioglitazone cause weight gain?
For a 21‑year‑old male with mild hypertension (office BP 153/82 mmHg, home average 122/65 mmHg), a small atrial septal defect, allergic rhinitis, mild hyperlipidaemia, and a BMI of 23, what ASA (American Society of Anesthesiologists) physical status classification is appropriate?
In a patient with ischemic hepatitis and an INR of 2.1 who is not bleeding, should fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) be administered?
After a patient has had a stroke and is being discontinued from clopidogrel, which medications should be continued indefinitely for secondary stroke prevention?
Can dietary supplements cause weight gain?
Is it safe to travel by airplane three months after an ischemic stroke and carotid artery stent placement?
Is the use of boric acid safe in a 13-year-old patient?
Should I document the patient's diagnosis as major depressive disorder in remission given a prior depressive episode, a PHQ‑9 score of 0, and ongoing maintenance therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.